Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection

Abstract From the Canadian patent

Compositions and methods disclosed herein capitalize on the discovery that rejection of a tissue graft can be inhibited using a CD40:CD154 binding interruptor, either alone or in combination with another immunomodulator or immunosuppressor. An advantageous, synergistic combination includes a CD40:CD154 binding interruptor and a CD28 signalling interruptor. An exemplary CD40:CD154 binding interruptor is an anti-CD154 monoclonal antibody such as , an antibody having the antigen-specific binding characteristics of the 5c8 monoclonal antibody. An exemplary CD28 signalling interruptor is a CTLA4-Ig fusion protein. The disclosed compositions and methods unexpectedly can be used to prolong …